Literature DB >> 25023353

Platelet effects on ovarian cancer.

Ashley N Davis1, Vahid Afshar-Kharghan2, Anil K Sood3.   

Abstract

Growing understanding of the role of thrombocytosis, high platelet turnover, and the presence of activated platelets in the circulation in cancer progression and metastasis has brought megakaryocytes into focus. Platelet biology is essential to hemostasis, vascular integrity, angiogenesis, inflammation, innate immunity, wound healing, and cancer biology. However, before megakaryocyte/platelet-directed therapies can be considered for clinical use, understanding of the mechanism and biology of paraneoplastic thrombocytosis in malignancy is required. Here, we provide an overview of the clinical implications, biological significance, and mechanisms of paraneoplastic thrombocytosis in the context of ovarian cancer.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25023353      PMCID: PMC4100073          DOI: 10.1053/j.seminoncol.2014.04.004

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  62 in total

Review 1.  Surgical management of ovarian cancer.

Authors:  David G Mutch
Journal:  Semin Oncol       Date:  2002-02       Impact factor: 4.929

2.  Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance.

Authors:  A Radziwon-Balicka; C Medina; L O'Driscoll; A Treumann; D Bazou; I Inkielewicz-Stepniak; A Radomski; H Jow; M W Radomski
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

3.  Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.

Authors:  Agnes Y Y Lee; Frederick R Rickles; Jim A Julian; Michael Gent; Ross I Baker; Chris Bowden; Ajay K Kakkar; Martin Prins; Mark N Levine
Journal:  J Clin Oncol       Date:  2005-02-07       Impact factor: 44.544

4.  Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival.

Authors:  Joshua G Cohen; Arthur-Quan Tran; B J Rimel; Ilana Cass; Christine S Walsh; Beth Y Karlan; Andrew J Li
Journal:  Gynecol Oncol       Date:  2014-01-11       Impact factor: 5.482

5.  Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.

Authors:  Christina Fotopoulou; Andreas duBois; Alexandros N Karavas; Ralf Trappe; Behnaz Aminossadati; Barbara Schmalfeldt; Jacobus Pfisterer; Jalid Sehouli
Journal:  J Clin Oncol       Date:  2008-06-01       Impact factor: 44.544

6.  Venous thromboembolism prophylaxis in gynecologic oncology: a prospective, controlled trial of low-dose heparin.

Authors:  D L Clarke-Pearson; R E Coleman; I S Synan; W Hinshaw; W T Creasman
Journal:  Am J Obstet Gynecol       Date:  1983-03-01       Impact factor: 8.661

7.  Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells.

Authors:  Karl Egan; Darragh Crowley; Paul Smyth; Sharon O'Toole; Cathy Spillane; Cara Martin; Michael Gallagher; Aoife Canney; Lucy Norris; Niamh Conlon; Lynda McEvoy; Brendan Ffrench; Britta Stordal; Helen Keegan; Stephen Finn; Victoria McEneaney; Alex Laios; Jens Ducrée; Eimear Dunne; Leila Smith; Michael Berndt; Orla Sheils; Dermot Kenny; John O'Leary
Journal:  PLoS One       Date:  2011-10-12       Impact factor: 3.240

8.  Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium.

Authors:  Britton Trabert; Roberta B Ness; Wei-Hsuan Lo-Ciganic; Megan A Murphy; Ellen L Goode; Elizabeth M Poole; Louise A Brinton; Penelope M Webb; Christina M Nagle; Susan J Jordan; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Galina Lurie; Susanne K Kjær; Estrid Hogdall; Allan Jensen; Daniel W Cramer; Kathryn L Terry; Allison Vitonis; Elisa V Bandera; Sara Olson; Melony G King; Urmila Chandran; Hoda Anton-Culver; Argyrios Ziogas; Usha Menon; Simon A Gayther; Susan J Ramus; Aleksandra Gentry-Maharaj; Anna H Wu; Celeste Leigh Pearce; Malcolm C Pike; Andrew Berchuck; Joellen M Schildkraut; Nicolas Wentzensen
Journal:  J Natl Cancer Inst       Date:  2014-02       Impact factor: 11.816

9.  Prognosis of ovarian cancer subsequent to venous thromboembolism: a nationwide Danish cohort study.

Authors:  Mette S Tetsche; Mette Nørgaard; Lars Pedersen; Timothy L Lash; Henrik T Sørensen
Journal:  BMC Cancer       Date:  2006-07-17       Impact factor: 4.430

Review 10.  First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence.

Authors:  J Sandercock; M K B Parmar; V Torri; W Qian
Journal:  Br J Cancer       Date:  2002-10-07       Impact factor: 7.640

View more
  23 in total

1.  OvCa-Chip microsystem recreates vascular endothelium-mediated platelet extravasation in ovarian cancer.

Authors:  Biswajit Saha; Tanmay Mathur; Katelyn F Handley; Wei Hu; Vahid Afshar-Kharghan; Anil K Sood; Abhishek Jain
Journal:  Blood Adv       Date:  2020-07-28

2.  Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer.

Authors:  Yan Huang; Lenard M Lichtenberger; Morgan Taylor; Justin N Bottsford-Miller; Monika Haemmerle; Michael J Wagner; Yasmin Lyons; Sunila Pradeep; Wei Hu; Rebecca A Previs; Jean M Hansen; Dexing Fang; Piotr L Dorniak; Justyna Filant; Elizabeth J Dial; Fangrong Shen; Hiroto Hatakeyama; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2016-09-16       Impact factor: 6.261

3.  Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study.

Authors:  Melissa A Merritt; Megan S Rice; Mollie E Barnard; Susan E Hankinson; Ursula A Matulonis; Elizabeth M Poole; Shelley S Tworoger
Journal:  Lancet Oncol       Date:  2018-07-18       Impact factor: 41.316

Review 4.  Mechanisms and Targets Involved in Dissemination of Ovarian Cancer.

Authors:  Ulrich H Weidle; Fabian Birzele; Gwendlyn Kollmorgen; Rüdiger Rueger
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

5.  Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.

Authors:  Koji Matsuo; Kosei Hasegawa; Kiyoshi Yoshino; Ryusuke Murakami; Takeshi Hisamatsu; Rebecca L Stone; Rebecca A Previs; Jean M Hansen; Yuji Ikeda; Akiko Miyara; Kosuke Hiramatsu; Takayuki Enomoto; Keiichi Fujiwara; Noriomi Matsumura; Ikuo Konishi; Lynda D Roman; Hani Gabra; Christina Fotopoulou; Anil K Sood
Journal:  Eur J Cancer       Date:  2015-07-31       Impact factor: 9.162

6.  DNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer.

Authors:  Lian Li; Hong Zheng; Yubei Huang; Caiyun Huang; Shuang Zhang; Jing Tian; Pei Li; Anil K Sood; Wei Zhang; Kexin Chen
Journal:  Carcinogenesis       Date:  2017-08-01       Impact factor: 4.741

7.  Platelets enhance tissue factor protein and metastasis initiating cell markers, and act as chemoattractants increasing the migration of ovarian cancer cells.

Authors:  Renan Orellana; Sumie Kato; Rafaela Erices; María Loreto Bravo; Pamela Gonzalez; Bárbara Oliva; Sofía Cubillos; Andrés Valdivia; Carolina Ibañez; Jorge Brañes; María Isabel Barriga; Erasmo Bravo; Catalina Alonso; Eva Bustamente; Enrique Castellon; Patricia Hidalgo; Cesar Trigo; Olga Panes; Jaime Pereira; Diego Mezzano; Mauricio A Cuello; Gareth I Owen
Journal:  BMC Cancer       Date:  2015-04-15       Impact factor: 4.430

Review 8.  Targeting Platelets for the Treatment of Cancer.

Authors:  Omar Elaskalani; Michael C Berndt; Marco Falasca; Pat Metharom
Journal:  Cancers (Basel)       Date:  2017-07-22       Impact factor: 6.639

9.  Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records.

Authors:  Gabriella D Cozzi; Jacob M Samuel; Jason T Fromal; Spencer Keene; Marta A Crispens; Dineo Khabele; Alicia Beeghly-Fadiel
Journal:  BMC Cancer       Date:  2016-08-08       Impact factor: 4.430

10.  Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.

Authors:  E Sun Paik; Insuk Sohn; Sun-Young Baek; Minhee Shim; Hyun Jin Choi; Tae-Joong Kim; Chel Hun Choi; Jeong-Won Lee; Byoung-Gie Kim; Yoo-Young Lee; Duk-Soo Bae
Journal:  Cancer Res Treat       Date:  2016-09-27       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.